TERN-101 is a potent, non-bile acid farnesoid X receptor (FXR) agonist. FXR activation has been shown to prevent the progression from histological liver fibrosis to NASH. The designation was based ...

The farnesoid-X receptor (FXR), also known as the chief regulator of bile acid metabolism, is thought to play a role in some hepatobiliary and gastrointestinal disorders. In a study published in ...

Reference: Renga B, Mencarelli A, Migliorati M, Distrutti E, Fiorucci S. Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation. World J ...

6.1% with placebo. FXR314 was well-tolerated, without the adverse events associated with farnesoid X receptor agonists. SAN DIEGO — Once-daily FXR314 was well-tolerated and safely improved liver ...

In a recent study published in Nature, researchers assessed the association between farnesoid X receptor (FXR) inhibition and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 ...

Therapeutic strategies targeting this pathway include peroxisome proliferator-activated receptor (PPAR) agonists, bile acid-farnesoid X receptor (FXR) agonists, and de novo lipogenesis (DNL ...

April 19, 2010 (Vienna, Austria) — A new receptor agonist for regulation ... interest of researchers with the discovery of the farnesoid-X receptor (FXR) and the newfound role of bile acids ...

Expected to add $33 million in cash at closing to Equillium’s balance sheet and extend operating runway into 2024 Through the acquisition, Equillium adds Metacrine’s farnesoid X receptor (FXR ...

After reviewing data from its phase II trial of farnesoid X receptor agonist ASC-42 in primary biliary cholangitis, Ascletis Pharma Inc. said it was quitting development of the molecule in all ...

The farnesoid-X receptor (FXR), also known as the chief regulator of bile acid metabolism, is thought to play a role in some hepatobiliary and gastrointestinal disorders.